The rapid advances being made in unravelling the biochemistry and function of the three categories of adhesion molecule involved in leucocyte-endothelial-cell interactions, namely selectins, integrins and the Ig super-family molecules, were highlighted at a recent meeting. In this short report, Nancy Hogg describes these developments and the prospects for anti-adhesion molecule therapy in the clinic.